Safety of Amiodarone and Ranolazine Together in Patients With Angina

Status unconfirmed · Phase 4 · Has a placebo group

Conditions studied: Chronic Stable Angina, Coronary Artery Disease, Atrial Fibrillation, Ventricular Tachycardia

In brief

Ranolazine is an effective and remarkably safe agent for the treatment of patients with chronic stable angina, but its inhibition of voltage gated potassium channels and electrocardiogram (EKG) corrected QT (QTc) prolongation properties have lead many to question its safety when combined with antiarrhythmic drugs. The investigators have proposed a study to determine the safety of ranolazine in patients with chronic stable angina who also take amiodarone. And are conducting a prospective single-center randomized single-blinded placebo controlled trial to run out of our large cardiology practice setting at Cardiovascular Consultants of Nevada. The hypothesis is that there will be no difference in the ventricular arrhythmia burden. The primary outcome will be the measurement of ventricular arrhythmia episodes on serial holter monitor and other serially acquired recordings (such as electrocardiogram, pacemaker or implantable defibrillator (ICD) data, and stress test data) over a three month trial period.

Key facts

Study ID
NCT01558830
Run by
Cardiovascular Consultants of Nevada
People needed
50
Starts
2012-01-01
Expected to finish
2013-07-01
Last updated by the study team
2012-03-21

Who can join

Age: 35 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.